Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ezutromid - Summit Therapeutics

Next Previous
X
Search
Drug Profile

Ezutromid - Summit Therapeutics

Alternative Names: BMN-195; SMT-1100; SMTC-1100; VOX-C1100

Latest Information Update: 02 Oct 2021

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator VASTox
  • Developer Summit Therapeutics
  • Class Benzoxazoles; Naphthalenes; Small molecules; Sulfoxides
  • Mechanism of Action Utrophin modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Duchenne muscular dystrophy
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Duchenne muscular dystrophy

Most Recent Events

  • 27 Aug 2018 Summit Therapeutics completes a phase II clinical trials in Duchenne muscular dystrophy (In children) in United Kingdom and USA (PO) (EudraCT2015-004333-27) (NCT02858362)
  • 27 Jun 2018 Summit Therapeutics withdraws a phase II trial for Duchenne muscular dystrophy in USA and Europe prior to enrolment
  • 27 Jun 2018 Discontinued - Phase-I for Duchenne muscular dystrophy (In adults) in United Kingdom following failure to meet primary endpoint (PO)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top